Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Gary Robb Biography and Net Worth

CFO of Corcept Therapeutics

Gary Charles Robb serves as Chief Financial Officer, Secretary of the Company. From 2005 to 2011, Mr. Robb served as the Senior Vice President of Operations, Administration and Finance of Fitness Anywhere, Inc., a private fitness equipment and training company with operations in the United States, Europe and Asia. From 2003 to 2005, Mr. Robb was engaged in the private practice of law. From 2000 to 2002, he was Senior Vice President of Citadon, Inc. He also held positions in business development for Nomura Asset Capital Corporation from 1998 to 1999 and in sales and marketing for Legal Research Network, Inc. from 1996 to 1998. From 1992 to 1996, Mr. Robb practiced law at Howard, Rice, Nemerovski, Canady, Falk & Rabkin. Mr. Robb earned a B.A. in English and Political Philosophy from Yale and a J.D. from Harvard Law School.

What is Gary Charles Robb's net worth?: The estimated net worth of Gary Charles Robb is at least $1.17 million as of October 1st, 2024. Mr. Robb owns 22,772 shares of Corcept Therapeutics stock worth more than $1,170,481 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Robb may own. Additionally, Mr. Robb receives an annual salary of $1,080,000.00 as CFO at Corcept Therapeutics. Learn More about Gary Charles Robb's net worth.
How old is Gary Charles Robb?: Mr. Robb is currently 61 years old. There are 7 older executives and no younger executives at Corcept Therapeutics. The oldest executive at Corcept Therapeutics is Dr. Joseph K. Belanoff M.D., Co-Founder, President, CEO & Director, who is 67 years old. Learn More on Gary Charles Robb's age.
What is Gary Charles Robb's salary?: As the CFO of Corcept Therapeutics Incorporated, Mr. Robb earns $1,080,000.00 per year. The highest earning executive at Corcept Therapeutics is Dr. Joseph K. Belanoff M.D., Co-Founder, President, CEO & Director, who commands a salary of $2,430,000.00 per year. Learn More on Gary Charles Robb's salary.
How do I contact Gary Charles Robb?: The corporate mailing address for Mr. Robb and other Corcept Therapeutics executives is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. Corcept Therapeutics can also be reached via phone at (650) 327-3270 and via email at [email protected]. Learn More on Gary Charles Robb's contact information.
Has Gary Charles Robb been buying or selling shares of Corcept Therapeutics?: During the last ninety days, Gary Charles Robb has sold $509,080.00 in shares of Corcept Therapeutics stock. Most recently, Gary Charles Robb sold 11,000 shares of the business's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $46.28, for a transaction totalling $509,080.00. Following the completion of the sale, the insider now directly owns 22,772 shares of the company's stock, valued at $1,053,888.16. Learn More on Gary Charles Robb's trading history.
Who are Corcept Therapeutics' active insiders?: Corcept Therapeutics' insider roster includes G. Baker, Jr. (Director), Joseph Belanoff (CEO), William Guyer (Chief Development Officer), Hazel Hunt (Insider), Joseph Lyon (CAO), Sean Maduck (Insider), David Mahoney (Director), Gary Robb (CFO), and Daniel Swisher, Jr. (Director). Learn More on Corcept Therapeutics' active insiders.
Are insiders buying or selling shares of Corcept Therapeutics?: In the last year, insiders at the biotechnology company sold shares 29 times. They sold a total of 239,502 shares worth more than $7,340,976.12. The most recent insider tranaction occured on December, 10th when Director Daniel N. Swisher, Jr. sold 2,200 shares worth more than $130,812.00. Insiders at Corcept Therapeutics own 20.5% of the company. Learn More about insider trades at Corcept Therapeutics.
Information on this page was last updated on 12/10/2024.

Gary Charles Robb Insider Trading History at Corcept Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/1/2024	Sell	11,000	$46.28	$509,080.00	22,772
8/26/2024	Sell	3,101	$35.71	$110,736.71	23,190
5/28/2024	Sell	11,000	$30.39	$334,290.00	20,203
12/5/2023	Sell	1,381	$26.27	$36,278.87	27,602
5/9/2023	Sell	30,000	$23.87	$716,100.00	33,997
11/22/2022	Sell	4,814	$26.03	$125,308.42	21,329
11/17/2022	Sell	10,000	$26.06	$260,600.00	39,544
9/7/2022	Sell	50,000	$26.06	$1,303,000.00	49,544
7/6/2022	Sell	45,000	$26.00	$1,170,000.00	24,123
5/19/2022	Sell	6,127	$19.57	$119,905.39	36,446
5/17/2022	Sell	28,745	$19.55	$561,964.75	42,701
3/17/2022	Sell	7,512	$24.68	$185,396.16
9/15/2021	Sell	47,853	$20.49	$980,507.97
9/13/2021	Sell	6,341	$20.89	$132,463.49	136,507
4/23/2021	Sell	10,000	$24.02	$240,200.00	75,638
2/12/2021	Sell	112,100	$28.22	$3,163,462.00	197,738
12/12/2018	Sell	25,000	$19.01	$475,250.00	21,858
5/4/2017	Buy	5,600	$9.75	$54,600.00	6,858

Gary Charles Robb Buying and Selling Activity at Corcept Therapeutics

Corcept Therapeutics Company Overview

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Today's Range

Now: $51.40

$50.02

$52.35

50 Day Range

MA: $53.83

$45.30

$60.85

2 Week Range

Now: $51.40

$20.84

$62.22

Volume

2,456,297 shs

Average Volume

1,158,141 shs

Market Capitalization

$5.39 billion

P/E Ratio

40.79

Dividend Yield

N/A

Beta

0.51

Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

From Weiss Ratings | Ad

Find out details on these three critical Nvidia partners immediately.

Gary Robb Biography and Net Worth

What is Gary Charles Robb's net worth?

How old is Gary Charles Robb?

What is Gary Charles Robb's salary?

How do I contact Gary Charles Robb?

Has Gary Charles Robb been buying or selling shares of Corcept Therapeutics?

Who are Corcept Therapeutics' active insiders?

Are insiders buying or selling shares of Corcept Therapeutics?